(Q36780117)

16 August 2017

1 reference

title

New hepatitis B vaccine formulated with an improved adjuvant system (English)

1 reference

16 August 2017

1 reference

1 reference

1 reference

1

Michael Kundi

1 reference

16 August 2017

publication date

1 April 2007

1 reference

Expert Review of Vaccines

16 August 2017

published in

1 reference

16 August 2017

volume

6

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

133-140

1 reference

Epidemiology of hepatitis B in Europe and worldwide

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Hepatitis B virus infection: epidemiology and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Global epidemiology of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

A "NEW" ANTIGEN IN LEUKEMIA SERA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Hepatitis B virus. The major etiology of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Immunogenicity of Twinrix in older adults: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

HBV infection in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

(How) do aluminium adjuvants work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Adjuvants--a balance between toxicity and adjuvanticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

A prophylactic hepatitis B vaccine with a novel adjuvant system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Improved survival in patients with type 1 diabetes mellitus after renal transplantation compared with hemodialysis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Renal replacement therapy in patients with diabetes and end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Hepatitis B and C and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

National surveillance of dialysis-associated diseases in the United States, 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

An outbreak of fulminant hepatitis B in immunocompromised hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Are booster immunisations needed for lifelong hepatitis B immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

A hepatitis B vaccine formulated with a novel adjuvant system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.133

21 January 2018

Identifiers

DOI

10.1586/14760584.6.2.133

1 reference

16 August 2017

1 reference